Security Snapshot

Beam Therapeutics Inc. - Common Stock (BEAM) Institutional Ownership

CUSIP: 07373V105

13F Institutional Holders and Ownership History from Q1 2020 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

276

Shares (Excl. Options)

109,387,261

Price

$34.32

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+736,135
Value change
+$51,477,491
Number of holders
276
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
102,862,935
SEC-reported price per share
$26.71
Insider filing price
$26.71
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • BEAM - Beam Therapeutics Inc. - Common Stock is tracked under CUSIP 07373V105.
  • 276 institutions reported positions in Q2 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 253 to 276 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $2,579,087,708 to $3,753,444,539.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 276 institutions filings for Q2 2026.

Open SEC evidence

Security key

07373V105

Latest holder period

Q2 2026

13F holders

276

13D/G owners

8

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
BEAM
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 13% -7.1% $353,440,240 -$28,167,623 12,750,369 -7.4% FMR LLC 31 Dec 2025
FARALLON CAPITAL MANAGEMENT, L.L.C. 10% $368,308,762 10,282,210 Farallon Capital Management, L.L.C. 30 Jun 2026
ARK Investment Management LLC 10% -20% $366,612,757 -$79,961,953 10,234,862 -18% ARK Investment Management LLC 30 Jun 2026
Farallon Capital Partners, L.P. 10% 0% $281,132,248 +$4,681,243 10,141,856 +1.7% Dapice Joshua J. 31 Dec 2025
BlackRock, Inc. 7.5% $147,823,620 7,499,930 BlackRock, Inc. 31 Mar 2025
STATE STREET CORP 5.2% $144,934,824 5,228,529 STATE STREET CORPORATION 31 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC 5% $122,068,579 5,122,475 Vanguard Capital Management 31 Mar 2026
ARCH Venture Fund IX, L.P. 4.6% -17% $90,680,723 4,600,747 0% Robert Nelsen 31 Mar 2025

As of 30 Jun 2026, 276 institutional investors reported holding 109,387,261 shares of Beam Therapeutics Inc. - Common Stock (BEAM). This represents 106% of the company’s total 102,862,935 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
92%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 12% 12,609,002 +1.3% 0.02% $432,740,939
FARALLON CAPITAL MANAGEMENT, L.L.C. 10% 10,236,396 +1% 2.1% $351,313,111
ARK Investment Management LLC 9.9% 10,234,862 -16% 2.3% $351,260,447
BlackRock, Inc. 8.7% 8,997,542 +6% 0% $308,795,642
STATE STREET CORP 5.7% 5,827,122 +2.2% 0.01% $199,986,827
VANGUARD PORTFOLIO MANAGEMENT LLC 4.8% 4,921,259 +7.7% 0.01% $168,897,609
VANGUARD CAPITAL MANAGEMENT LLC 4.5% 4,599,437 +5.1% 0% $157,852,678
ARCH Venture Management, LLC 4.4% 4,540,132 0% 14% $155,771,929
Sumitomo Mitsui Trust Group, Inc. 3.4% 3,455,043 -9.7% 0.07% $118,577,076
Amova Asset Management Americas, Inc. 3.4% 3,455,043 -9.7% 1.5% $118,542,525
PRICE T ROWE ASSOCIATES INC /MD/ 3.3% 3,415,239 +26% 0.01% $117,212,000
Kynam Capital Management, LP 2.8% 2,840,792 -23% 5.4% $97,495,981
GEODE CAPITAL MANAGEMENT, LLC 2.5% 2,596,963 +7.4% 0% $89,144,433
DIMENSIONAL FUND ADVISORS LP 2.2% 2,225,844 +3.3% 0.01% $76,396,796
MORGAN STANLEY 1.9% 1,950,968 +201% 0% $66,957,225
Contrarius Group Holdings Ltd 1.6% 1,614,538 +203% 2.6% $55,410,944
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 1.5% 1,551,781 -6.2% 0.01% $53,257,124
TWO SIGMA INVESTMENTS, LP 1.3% 1,388,227 +15% 0.04% $47,643,951
Casdin Capital, LLC 1.3% 1,350,000 0% 2.3% $46,332,000
GOLDMAN SACHS GROUP INC 1.3% 1,310,059 +30% 0% $44,961,225
Redmile Group, LLC 1.1% 1,164,259 -5.9% 2.7% $39,957,369
BNP PARIBAS FINANCIAL MARKETS 1% 1,067,883 0% 0.02% $36,649,745
Deep Track Capital, LP 0.97% 1,000,000 +22% 0.51% $34,320,000
NORTHERN TRUST CORP 0.91% 933,481 +13% 0% $32,037,069
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.86% 885,902 +9.6% 0% $30,404,157

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
26
Latest
Q2 2026
Rows shown
1-25 of 26
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 109,387,261 $3,753,444,539 +$51,477,491 $34.32 276
2026 Q1 108,284,269 $2,579,087,708 +$33,027,843 $23.83 253
2025 Q4 106,860,527 $2,962,657,242 +$15,891,836 $27.72 245
2025 Q3 106,531,653 $2,585,329,209 -$9,441,913 $24.27 214
2025 Q2 108,325,993 $1,842,599,951 +$102,159,924 $17.01 213
2025 Q1 101,329,623 $1,984,124,636 +$387,248,348 $19.53 234
2024 Q4 81,429,029 $2,019,888,804 +$52,922,730 $24.80 228
2024 Q3 78,929,001 $1,933,839,851 +$32,128,779 $24.50 217
2024 Q2 77,540,507 $1,816,892,862 +$138,460,483 $23.43 210
2024 Q1 70,332,894 $2,323,064,829 +$51,308,447 $33.04 217
2023 Q4 68,925,790 $1,876,215,663 +$46,457,918 $27.22 183
2023 Q3 67,439,160 $1,621,864,483 +$72,305,572 $24.05 190
2023 Q2 64,198,552 $2,049,551,170 +$123,991,732 $31.93 191
2023 Q1 60,372,846 $1,848,161,788 +$134,989,244 $30.62 205
2022 Q4 55,910,182 $2,186,652,051 +$42,258,811 $39.11 205
2022 Q3 54,633,598 $2,601,918,929 -$6,231,369 $47.64 214
2022 Q2 54,764,598 $2,088,902,541 +$192,782,034 $38.71 191
2022 Q1 49,225,196 $2,820,671,022 +$201,996,007 $57.30 230
2021 Q4 45,547,893 $3,629,719,477 -$39,454,291 $79.69 224
2021 Q3 45,176,306 $3,933,867,577 -$43,842,015 $87.01 223
2021 Q2 45,484,033 $5,854,372,685 +$342,578,385 $128.71 223
2021 Q1 43,012,900 $3,436,702,468 +$478,571,473 $80.04 203
2020 Q4 36,917,618 $3,014,269,128 +$632,622,766 $81.64 152
2020 Q3 29,525,955 $726,945,347 +$39,624,702 $24.62 84
2020 Q2 27,707,853 $775,554,484 +$34,103,632 $28.00 70
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .